Expert Interview
Exploring Guardant Health's Reveal® and BillionToOne's NorthStar Response® MRD liquid biopsy assays for cancer patient monitoring
Ticker(s): GH, BLLNInstitution: Costal Cancer Center
- Oncologist at Coastal Cancer Center in South Carolina.
- Manages 150 patients with solid tumors
- Very familiar with methylated circulating tumor DNA (ctDNA) and tissue-free approaches.
In your practice, where do you see methylation-based ctDNA assays adding the most value compared with mutation-based ctDNA or standard imaging?
Added By: emily_adminHow comfortable would you be using a tissue-free, methylation-based blood test to assess therapy response or early progression in late-stage solid tumors? What evidence would you need to see?
Added By: emily_adminOver the next 3–5 years, do you expect methylation-based ctDNA monitoring to become standard of care in certain cancers, or remain complementary to existing tools? Why?
Added By: emily_adminWhat are your thoughts on the recent GH expansion and potential of BillionToOne's NorthStar Response test?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
